$0.18
9.98% yesterday
Nasdaq, May 20, 09:50 pm CET
ISIN
US62856X1028
Symbol
TNFA

MyMD Pharmaceuticals Inc Stock price

$0.18
+0.01 4.43% 1M
-1.05 85.44% 6M
-0.97 84.43% YTD
-2.20 92.47% 1Y
-77.82 99.77% 3Y
-194.82 99.91% 5Y
-45,964.62 100.00% 10Y
Nasdaq, Closing price Tue, May 20 2025
-0.02 10.14%
ISIN
US62856X1028
Symbol
TNFA
Sector

Key metrics

Market capitalization $2.54m
Enterprise Value $1.96m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 0.15
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-8.35m
Free Cash Flow (TTM) Free Cash Flow $-9.70m
Cash position $5.88m
EPS (TTM) EPS $-6.95
Short interest 15.86%
Show more

Is MyMD Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

MyMD Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast MyMD Pharmaceuticals Inc:

Buy
100%

Financial data from MyMD Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.56 4.56
49% 49%
-
- Research and Development Expense 3.79 3.79
54% 54%
-
-8.35 -8.35
52% 52%
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -8.35 -8.35
52% 52%
-
Net Profit -15 -15
19% 19%
-

In millions USD.

Don't miss a Thing! We will send you all news about MyMD Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

MyMD Pharmaceuticals Inc Stock News

Neutral
Business Wire
13 days ago
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health, a company committed to focusing on outpatient care to minimize costs, impact and the need for hospitalization, today announced positive results fr...
Neutral
Business Wire
29 days ago
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, and Renova Health announce the application of AI and machine learning technologies to identify high-risk patient groups that may benefit the most from interventions ...
Neutral
Business Wire
about one month ago
BALTIMORE--(BUSINESS WIRE)---- $TNFA--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) (“TNF” or the “Company”), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, announced today that a platform presentation of an abstract titled “Isomyosamine for the Treatment of Sarcopenia in Older Adults” was delivered by Mitchell Glass, M....
More MyMD Pharmaceuticals Inc News

Company Profile

MyMD Pharmaceuticals, Inc. is a clinical stage pharmaceutical company which engages in extending healthy lifespan. It involves in developing and commercializing therapeutic platforms based on well-defined therapeutic targets, MYMD-1 and Supera-CBD. The company is headquartered in Baltimore, MD.

Head office United States
CEO Christopher Chapman
Employees 2
Founded 1989
Website tnfpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today